Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating." (3/25/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jill Wahleithner More >
Prior to joining Sagient Research, John Tucker was the director of medical chemistry for ChemBridge Corp. and before that served as principal scientist for Elan Corp. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV, antibacterials and Alzheimer's disease. Tucker received his doctorate in organic chemistry from UCLA, working in the research group of Nobel Laureate Donald Cram. Tucker also earned his master's degree in business administration from the Anderson School of Management at UCLA.
Lessons from the Liver Meeting: Sagient's John Tucker Names Companies that Could Reignite the Hepatitis C Industry (11/29/12) The hepatitis C (HCV) market was white hot in 2011 and through the beginning of 2012, but investors have gotten the message that new HCV drugs are not going to rival cancer and cardiovascular drugs for profits. In this interview with The Life Sciences Report, analyst John Tucker of Sagient Research discusses a handful of stocks that could benefit from new, patient-friendly HCV therapies with enough revenue to propel shares upward.
"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >
"STEM is doing pioneering work in the field of cervical spinal cord Injury and dry age-related macular degeneration." (4/8/15) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert More >